Douglas L Mann, Johny Nicolas, Brian Claggett, Zi Michael Miao, Christopher B Granger, Prafulla Kerkar, Lars Køber, Eldrin F Lewis, John J V McMurray, Aldo P Maggioni, Julio Núñez, Mpiko Ntsekhe, Jean-Lucien Rouleau, David Sim, Scott D Solomon, Philippe Gabriel Steg, Peter van der Meer, Eugene Braunwald, Marc A Pfeffer, Roxana Mehran
BACKGROUND: Patients who sustain an acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary events, and death. Angiotensin-converting enzyme inhibitors have been shown to significantly decrease the risk for cardiovascular events in both STEMI and NSTEMI patients. OBJECTIVES: The objectives were to determine whether angiotensin-receptor blockade and neprilysin inhibition with sacubitril/valsartan, compared with ramipril, has impact on reducing cardiovascular events according to the type of AMI...
March 5, 2024: Journal of the American College of Cardiology